Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

AstraZeneca PLC (AZN)

66.13   0.52 (0.79%) 03-20 09:55
Open: 65.58 Pre. Close: 65.61
High: 66.13 Low: 65.789
Volume: 628,443 Market Cap: 204,981(M)

Technical analysis

as of: 2023-03-20 9:14:32 AM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 79.39     One year: 82.43
Support: Support1: 63.77    Support2: 53.05
Resistance: Resistance1: 67.97    Resistance2: 70.58
Pivot: 65.01
Moving Average: MA(5): 65.28     MA(20): 65.81
MA(100): 66.1     MA(250): 64.63
MACD: MACD(12,26): -0.6     Signal(9): -0.7
Stochastic oscillator: %K(14,3): 47.4     %D(3): 35
RSI: RSI(14): 48.4
52-week: High: 72.12  Low: 52.65
Average Vol(K): 3-Month: 4,960 (K)  10-Days: 4,674 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AZN ] has closed below upper band by 29.4%. Bollinger Bands are 56.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 65.92 - 66.24 66.24 - 66.56
Low: 64.37 - 64.78 64.78 - 65.18
Close: 64.85 - 65.5 65.5 - 66.14

Company Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Headline News

Mon, 20 Mar 2023
CWA Asset Management Group LLC Purchases New Shares in ... - Defense World

Sat, 18 Mar 2023
Grant GrossMendelsohn LLC Acquires New Position in AstraZeneca ... - MarketBeat

Sat, 18 Mar 2023
AstraZeneca PLC (NASDAQ:AZN) Given Consensus Rating of "Hold ... - MarketBeat

Thu, 16 Mar 2023
AstraZeneca PLC is sold by Fred Alger Management LLC for ... - Best Stocks

Wed, 15 Mar 2023
Where Does AstraZeneca plc (AZN) Stock Fall in the Drug Manufacturers - General Field After It Has Gained 0.16% This Week? - InvestorsObserver

Tue, 14 Mar 2023
Tealwood Asset Management Inc. Has $2.76 Million Holdings in ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. 3,100 (M)
Shares Float 3,090 (M)
% Held by Insiders 0 (%)
% Held by Institutions 17.6 (%)
Shares Short 3,470 (K)
Shares Short P.Month 2,500 (K)

Stock Financials

EPS 1.07
EPS Est Next Qtl 0.44
EPS Est This Year 1.9
EPS Est Next Year 1.7
Book Value (p.s.) 11.94
Profit Margin (%) 7.4
Operating Margin (%) 20.2
Return on Assets (ttm) 5.5
Return on Equity (ttm) 8.6
Qtrly Rev. Growth -6.7
Gross Profit (p.s.) 11.52
Sales Per Share 14.3
EBITDA (p.s.) 4.48
Qtrly Earnings Growth 0
Operating Cash Flow 9,810 (M)
Levered Free Cash Flow 12,360 (M)

Stock Valuations

PE Ratio 61.31
PEG Ratio 1.1
Price to Book value 5.49
Price to Sales 4.58
Price to Cash Flow 20.73

Stock Dividends

Dividend 0.99
Forward Dividend 0
Dividend Yield 1.5%
Dividend Pay Date 2021-09-12
Ex-Dividend Date 2021-08-11
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.